Skip to main content
SpringerLink
Log in

FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation

  • Original Article
  • Published:
International Journal of Hematology Aims and scope Submit manuscript

Abstract

To investigate clinical characteristics and outcomes of transplantation in AML patients with FLT3-ITD/DNMT3A double mutation, we retrospectively analyzed 206 Chinese patients with AML after Sanger sequencing. Our analysis showed that AML patients with FLT3-ITD and DNMT3A R882 mutations had a higher white blood cell count and a lower complete remission (CR) rate after first induction chemotherapy. All 206 patients received allogeneic hematopoietic stem cell transplantation (allo-HSCT) in status of CR. These results indicate that AML patients with FLT3-ITD and DNMT3A R882 double mutation show a higher 2-year cumulative incidence of relapse (CIR), lower 2-year overall survival (OS) rate, and lower 2-year leukocyte-free survival (LFS) after allo-HSCT. The univariate and multivariate analyses confirmed that disease status prior to transplantation, FLT3-ITD, FLT3-ITD, and DNMT3A R882 double mutation were independent factors for poor prognosis after allo-HSCT. In summary, the present cohort study demonstrated that FLT3-ITD and DNMT3A R882 double mutation predicts poor prognosis in Chinese AML patients receiving chemotherapy or allo-HSCT treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Goryainova NV. The clinical significance of genetic mutations in acute myeloid leukemia. Lik Sprava. 2014;12:10–8.

    Google Scholar 

  2. Volpe G, Clarke M, Garcia P, Walton DS, Vegiopoulos A, Del Pozzo W, et al. Regulation of the Flt3 gene in haematopoietic stem and early progenitor cells. PLoS One. 2015;10(9):e0138257.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Pemmaraju N, Kantarjian H, Andreeff M, Cortes J, Ravandi F. Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia. Expert Opin Investig Drugs. 2014;23(7):943–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Govedarovic N, Marjanovic G. Frequency and prognostic impact of FLT3/ITD mutation in patients with acute myeloid leukaemia. J BUON. 2011;16(1):108–11.

    CAS  PubMed  Google Scholar 

  5. Peng HL, Zhang GS, Gong FJ, Shen JK, Zhang Y, Xu YX, et al. Fms-like tyrosine kinase (FLT) 3 and FLT3 internal tandem duplication in different types of adult leukemia: analysis of 147 patients. Croat Med J. 2008;49(5):650–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889–96.

    Article  CAS  PubMed  Google Scholar 

  7. Gaidzik VI, Schlenk RF, Paschka P, Stölzle A, Späth D, Kuendgen A, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of theAML Study Group (AMLSG). Blood. 2013;121(23):4769–77.

    Article  CAS  PubMed  Google Scholar 

  8. Kao HW, Liang DC, Kuo MC, Wu JH, Dunn P, Wang PN, et al. High frequency of additional gene mutations in acute myeloid leukemia with MLL partial tandem duplication: DNMT3A mutation is associated with poor prognosis. Oncotarget. 2015;6(32):33217–25.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–74.

    Article  Google Scholar 

  10. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366(12):1079–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. O’Donnell MR, Abboud CN, Altman J, Appelbaum FR, Arber DA, Attar E, et al. NCCN clinical practice guidelines acute myeloid leukemia. J Natl Compr Canc Netw. 2012;10(8):984–1021.

    Article  PubMed  Google Scholar 

  12. Wu X, He G, Fa Y, Ma X, Wu D, Ai H, et al. Comparable outcomes of partially matched related and matched related allogeneic hematopoietic cell transplantation following reduced-intensity conditioning in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Int J Hematol. 2013;98(4):456–62.

    Article  PubMed  Google Scholar 

  13. Tian H, Xu Y, Liu L, Yan L, Jin Z, Tang X, et al. Comparison of outcomes in mixed phenotype acute leukemia patients treated with chemotherapy and stemcell transplantation versus chemotherapy alone. Leuk Res. 2016;45:40–6.

    Article  CAS  PubMed  Google Scholar 

  14. Zhang YY, Liu DH, Liu KY, Xu LP, Chen H, Han W, et al. HLA-haploidentical hematopoietic SCT from collateral related donors without in vitro T-cell depletion for hematological malignancies. Bone Marrow Transpl. 2014;49(4):496–501.

    Article  Google Scholar 

  15. Lin PH, Lin CC, Yang HI, Li LY, Bai LY, Chiu CF, et al. Prognostic impact of allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. Leuk Res. 2013;37(3):287–92.

    Article  CAS  PubMed  Google Scholar 

  16. Xu Y, Sun Y, Shen H, Ding L, Yang Z. Qiu Het al: allogeneic hematopoietic stem cell transplantation could improve survival of cytogenetically normal adult acute myeloidleukemia patients with DNMT3A mutations. Am J Hematol. 2015;90(11):992–7.

    Article  CAS  PubMed  Google Scholar 

  17. Ofran Y, Rowe JM. Genetic profiling in acute myeloid leukaemia–where are we and what is its role in patient management. Br J Haematol. 2013;160(3):303–20.

    Article  CAS  PubMed  Google Scholar 

  18. Wu X, Feng X, Zhao X, Ma F, Liu N, Guo H, et al. Prognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies. Mol Cell Biochem. 2016;420(1–2):121–8.

    Article  CAS  PubMed  Google Scholar 

  19. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074–80.

    CAS  PubMed  Google Scholar 

  20. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood. 2001;98(6):1752–9.

    Article  CAS  PubMed  Google Scholar 

  21. Schmid C, Labopin M, Socie G, Daguindau E, Volin L, Huynh A, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 2015;126(17):2062–9.

    Article  CAS  PubMed  Google Scholar 

  22. Luskin MR, Carroll M, Lieberman D, Morrissette JJ, Zhao J, Crisalli L, et al. Clinical utility of next-generation sequencing for oncogenic mutations in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transpl. 2016;22(11):1961–7.

    Article  CAS  Google Scholar 

  23. Ahn JS, Kim HJ, Kim YK, Lee SS, Jung SH, Yang DH, et al. DNMT3A R882 Mutation with FLT3-ITD positivity is an extremely poor prognostic factor in patients with normal-karyotype acute myeloid leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016;22(1):61–70.

    Article  CAS  PubMed  Google Scholar 

  24. Yuan XQ, Peng L, Zeng WJ, Jiang BY, Li GC, Chen XP. DNMT3A R882 Mutations predict a poor prognosis in AML: a meta-analysis from 4474 patients. Medicine (Baltimore). 2016;95(18):e3519.

    Article  CAS  Google Scholar 

  25. Brunetti L, Gundry MC, Goodell MA. DNMT3A in Leukemia. Cold Spring Harb Perspect Med. 2017;7(2):a030320.

  26. Gale RE, Lamb K, Allen C, El-Sharkawi D, Stowe C, Jenkinson S, et al. Simpson’s Paradox and the impact of different DNMT3A mutations on outcome in younger adults with acute myeloid leukemia. J Clin Oncol. 2015;33(18):2072–83.

    Article  CAS  PubMed  Google Scholar 

  27. Gaidzik VI, Schlenk RF, Paschka P, Stolzle A, Spath D, Kuendgen A, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013;121(23):4769–77.

    Article  CAS  PubMed  Google Scholar 

  28. Russler-Germain DA, Spencer DH, Young MA, Lamprecht TL, Miller CA, Fulton R, et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell. 2014;25(4):442–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Yang L, Rodriguez B, Mayle A, Park HJ, Lin X, Luo M, et al. DNMT3A loss drives enhancer hypomethylation in FLT3-ITD-associated leukemias. Cancer Cell. 2016;29(6):922–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Wakita S, Yamaguchi H, Omori I, Terada K, Ueda T, Manabe E, et al. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia. 2013;27(5):1044–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported, in part, by research grants from the National Natural Science Foundation of China (81270645, 81470346, 81100390, 81100372), by Applied basic research of Suzhou science and technology progra (SYS201457), by Academic Program Development of Jiangsu Higher Education Institutions (PAPD) and The national key research and development program (2016YFC0902800), by Innovation Capability Development Project of Jiangsu Province (BM2015004).

Author information

Author notes

  1. Shanhao Tang, Hongjie Shen contributed equally to this work.

Authors and Affiliations

  1. Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, 188 Shizi Road, Suzhou, 215006, China

    Hongjie Shen, Haiping Dai, Xiaming Zhu, Shengli Xue, Zixuan Ding, Jing Lu, Depei Wu & Xiaowen Tang

  2. Institute of Blood and Marrow Transplantation, Suzhou, 215006, China

    Hongjie Shen, Haiping Dai, Xiaming Zhu, Shengli Xue, Zixuan Ding, Jing Lu, Depei Wu & Xiaowen Tang

  3. Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China

    Hongjie Shen, Haiping Dai, Xiaming Zhu, Shengli Xue, Zixuan Ding, Jing Lu, Depei Wu & Xiaowen Tang

  4. Department of Hematology, Yinzhou People Hospital, 251th, Baizhang East Road, Ningbo, 315040, China

    Shanhao Tang

  5. Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123, Jiangsu, China

    Xinliang Mao

Authors
  1. Shanhao Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hongjie Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xinliang Mao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Haiping Dai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xiaming Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shengli Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zixuan Ding
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jing Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Depei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Xiaowen Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Depei Wu or Xiaowen Tang.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interests.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 11 kb)

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tang, S., Shen, H., Mao, X. et al. FLT3-ITD with DNMT3A R882 double mutation is a poor prognostic factor in Chinese patients with acute myeloid leukemia after chemotherapy or allogeneic hematopoietic stem cell transplantation. Int J Hematol 106, 552–561 (2017). https://doi.org/10.1007/s12185-017-2256-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12185-017-2256-7

Keywords

Search

Navigation